Lipid-polymer nanoparticles encapsulating doxorubicin and 2′-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 1901-1909

  Su, Xianwei ^a   Wang, Zhaohui ^a   Li, Lili ^a,c   Zheng, Mingbin ^a,b   Zheng, Cuifang ^a   Gong, Ping ^a   Zhao, Pengfei ^a   Ma, Yifan ^a   Tao, Qian ^a,c   Cai, Lintao ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cancer therapy; chemotherapeutic drug; combined therapy; drug delivery; epigenetic drug

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DOXORUBICIN; MACROGOL; NANOPARTICLE; POLYGLACTIN; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; AZACITIDINE; DECITABINE; LACTIC ACID; MACROGOL DERIVATIVE; NANOCAPSULE; PHOSPHATIDYLETHANOLAMINE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EPIGENETICS; FEMALE; GENE EXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; INTERNALIZATION; NANOENCAPSULATION; NANOFABRICATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; GENETIC EPIGENESIS; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HUMANS; LACTIC ACID; NANOCAPSULES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 84877279679     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300675c     Document Type: Article

References (36)

1. Singal, P. K.; Iliskovic, N. Doxorubicin-Induced Cardiomyopathy N. Engl. J. Med. 1998, 339, 900-905
2. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
3. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy Adv. Drug Delivery Rev. 2004, 56, 1649-1659
4. Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications Nano Lett. 2010, 10, 3223-3230
5. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 2001, 41, 189-207
6. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986, 46, 6387-6392
7. Chang, A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC Lung Cancer 2011, 71, 3-10
8. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 2005, 436, 568-572
9. Coley, H. M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer Cancer Treat. Rev. 2008, 34, 378-390
10. Lai, D.; Visser-Grieve, S.; Yang, X. Tumour suppressor genes in chemotherapeutic drug response Biosci. Rep. 2012, 32, 361-374
11. Fojo, T.; Bates, S. Strategies for reversing drug resistance Oncogene 2003, 22, 7512-7523
12. Lage, H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance Curr. Drug Targets 2006, 7, 813-821
13. Perez, J.; Bardin, C.; Rigal, C.; Anthony, B.; Rousseau, R.; Dutour, A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines Anticancer Res. 2011, 31, 2813-2820
14. Abbasi, M.; Aliabadi, H. M.; Moase, E. H.; Lavasanifar, A.; Kaur, K.; Lai, R.; Doillon, C.; Uludag, H. siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice Pharm. Res. 2011, 28, 2516-2529
15. Xia, Z.; Zhu, Z.; Zhang, L.; Royal, C.; Liu, Z.; Chen, Q.; Adam, B. L. Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells Oncol. Rep. 2008, 20, 1433-1439
16. Chen, A. M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T.; He, H. Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells Small 2009, 5, 2673-2677
17. Baylin, S. B.; Ohm, J. E. Epigenetic gene silencing in cancer- A mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 2006, 6, 107-116
18. Jones, P. A.; Baylin, S. B. The epigenomics of cancer Cell 2007, 128, 683-692
19. Reid, G. K.; Besterman, J. M.; MacLeod, A. R. Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment Curr. Opin. Mol. Ther. 2002, 4, 130-137
20. Kuendgen, A.; Lubbert, M. Current status of epigenetic treatment in myelodysplastic syndromes Ann. Hematol. 2008, 87, 601-611
21. Mund, C.; Lyko, F. Epigenetic cancer therapy: Proof of concept and remaining challenges BioEssays 2010, 32, 949-957
22. Arnold, C. N.; Goel, A.; Boland, C. R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines Int. J. Cancer 2003, 106, 66-73
23. Jin, H.; Wang, X.; Ying, J.; Wong, A. H.; Cui, Y.; Srivastava, G.; Shen, Z. Y.; Li, E. M.; Zhang, Q.; Jin, J.; Kupzig, S.; Chan, A. T.; Cullen, P. J.; Tao, Q. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12353-12358
24. Murray, P. G.; Qiu, G. H.; Fu, L.; Waites, E. R.; Srivastava, G.; Heys, D.; Agathanggelou, A.; Latif, F.; Grundy, R. G.; Mann, J. R.; Starczynski, J.; Crocker, J.; Parkes, S. E.; Ambinder, R. F.; Young, L. S.; Tao, Q. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma Oncogene 2004, 23, 1326-1331
25. Kaminskyy, V. O.; Surova, O. V.; Vaculova, A.; Zhivotovsky, B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL Carcinogenesis 2011, 32, 1450-1458
26. Plumb, J. A.; Strathdee, G.; Sludden, J.; Kaye, S. B.; Brown, R. Reversal of Drug Resistance in Human Tumor Xenografts by 2′-Deoxy-5-azacytidine- induced Demethylation of the hMLH1 Gene Promoter Cancer Res. 2000, 60, 6039-6044
27. Xu, J.; Zhou, J. Y.; Tainsky, M. A.; Wu, G. S. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin Cancer Res. 2007, 67, 1203-1211
28. Shang, D.; Liu, Y.; Liu, Q.; Zhang, F.; Feng, L.; Lv, W.; Tian, Y. Synergy of 5-aza-2′-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines Cancer Lett. 2009, 278, 82-87
29. George, R. E.; Lahti, J. M.; Adamson, P. C.; Zhu, K.; Finkelstein, D.; Ingle, A. M.; Reid, J. M.; Krailo, M.; Neuberg, D.; Blaney, S. M.; Diller, L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study Pediatr. Blood Cancer 2010, 55, 629-638
30. Zheng, C.; Zheng, M.; Gong, P.; Jia, D.; Zhang, P.; Shi, B.; Sheng, Z.; Ma, Y.; Cai, L. Indocyanine green-loaded biodegradable tumor targeting nanoprobes for in vitro and in vivo imaging Biomaterials 2012, 33, 5603-5609
31. Lin, K.-T.; Momparlerm, R. L.; Rivard, G. E. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine J. Pharm. Sci. 1981, 70, 1228-1232
32. Wei, G.; Xiao, S.; Si, D.; Liu, C. Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations Biomed. Chromatogr. 2008, 22, 1252-1258
33. Qiu, G. H.; Salto-Tellez, M.; Ross, J. A.; Yeo, W.; Cui, Y.; Wheelhouse, N.; Chen, G. G.; Harrison, D.; Lai, P.; Tao, Q.; Hooi, S. C. The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle J. Hepatol. 2008, 48, 433-441
34. Seng, T. J.; Low, J. S. W.; Li, H.; Cui, Y.; Goh, H. K.; Wong, M. L. Y.; Srivastava, G.; Sidransky, D.; Califano, J.; Steenbergen, R. D. M.; Rha, S. Y.; Tan, J.; Hsieh, W. S.; Ambinder, R. F.; Lin, X.; Chan, A. T. C.; Tao, Q. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation Oncogene 2006, 26, 934-944
35. Zhang, Q.; Ying, J.; Zhang, K.; Li, H.; Ng, K. M.; Zhao, Y.; He, Q.; Yang, X.; Xin, D.; Liao, S. K.; Tao, Q.; Jin, J. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma Cancer Lett. 2007, 249, 220-226
36. Li, B.; Xu, H.; Li, Z.; Yao, M.; Xie, M.; Shen, H.; Shen, S.; Wang, X.; Jin, Y. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies Int. J. Nanomed. 2012, 7, 187-197